Fintel reports that on May 14, 2025, Citigroup upgraded their outlook for Regeneron Pharmaceuticals (NasdaqGS:REGN) from Neutral to Buy.
Analyst Price Forecast Suggests 44.26% Upside
As of May 6, 2025, the average one-year price target for Regeneron Pharmaceuticals is $824.33/share. The forecasts range from a low of $540.35 to a high of $1,063.65. The average price target represents an increase of 44.26% from its latest reported closing price of $571.44 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Regeneron Pharmaceuticals is 13,642MM, a decrease of 3.15%. The projected annual non-GAAP EPS is 46.86.
What is the Fund Sentiment?
There are 2,406 funds or institutions reporting positions in Regeneron Pharmaceuticals. This is an decrease of 46 owner(s) or 1.88% in the last quarter. Average portfolio weight of all funds dedicated to REGN is 0.35%, an increase of 102.18%. Total shares owned by institutions increased in the last three months by 0.44% to 112,200K shares. 
The put/call ratio of REGN is 0.95, indicating a bullish outlook.
What are Other Shareholders Doing?
Jpmorgan Chase holds 5,658K shares representing 5.45% ownership of the company. In its prior filing, the firm reported owning 7,059K shares , representing a decrease of 24.76%. The firm decreased its portfolio allocation in REGN by 92.61% over the last quarter.
Capital International Investors holds 3,989K shares representing 3.84% ownership of the company. In its prior filing, the firm reported owning 4,737K shares , representing a decrease of 18.75%. The firm decreased its portfolio allocation in REGN by 21.50% over the last quarter.
VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 3,387K shares representing 3.26% ownership of the company. In its prior filing, the firm reported owning 3,438K shares , representing a decrease of 1.50%. The firm decreased its portfolio allocation in REGN by 34.21% over the last quarter.
VFINX - Vanguard 500 Index Fund Investor Shares holds 2,849K shares representing 2.74% ownership of the company. In its prior filing, the firm reported owning 2,779K shares , representing an increase of 2.46%. The firm decreased its portfolio allocation in REGN by 34.28% over the last quarter.
Geode Capital Management holds 2,470K shares representing 2.38% ownership of the company. In its prior filing, the firm reported owning 2,428K shares , representing an increase of 1.70%. The firm decreased its portfolio allocation in REGN by 51.47% over the last quarter.
Regeneron Pharmaceuticals Background Information
(This description is provided by the company.)
Regeneron is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for over 30 years by physician-scientists, its unique ability to repeatedly and consistently translate science into medicine has led to nine FDA-approved treatments and numerous product candidates in development, almost all of which were homegrown in its laboratories. Its medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, infectious diseases and rare diseases.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
